UPDATE 2-Bristol-Myers forecasts 2016 profit above Wall Street estimates

Jan 28 (Reuters) - Bristol-Myers Squibb Co forecast 2016 earnings slightly above Wall Street estimates and said it had halted a large trial of its Opdivo immuno-oncology drug after an independent monitoring committee concluded it prolonged survival compared to standard therapy for head and neck cancer.